With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.

Fengting Yan, MD, PhD, discusses the challenge of balancing clinical judgment with genomic test results in breast cancer.

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, ...